Recent research highlights a concerning association between the weight-loss drug Wegovy and a significantly increased risk of sudden vision loss, suggesting that users may face nearly five times the risk compared to those taking its diabetes counterpart, Ozempic. This alarming finding raises important questions about the safety profile of semaglutide, the active ingredient in both medications, and its implications for patients seeking effective obesity treatment.
The Study’s Findings
A comprehensive study published in the *British Journal of Ophthalmology* investigated the adverse effects associated with glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications, including semaglutide and tirzepatide, which are known for their ability to lower blood sugar levels, curb appetite, and offer various health benefits. However, the research revealed that Wegovy users exhibited a fivefold increased likelihood of developing non-arteritic anterior ischemic optic neuropathy (Naion) – a condition colloquially referred to as an “eye stroke” – compared to Ozempic users.
Dr Edward Margolin, from the University of Toronto’s ophthalmology department and a co-author of the study, noted that Naion could be a genuine side effect of semaglutide. He suggested that rapid weight loss associated with Wegovy may exacerbate this risk, particularly among men, who were found to be at a threefold greater risk than women.
Understanding Naion
Naion occurs when blood flow to the optic nerve is compromised, leading to sudden and often irreversible vision loss. Although the condition is rare, affecting approximately one in 10,000 individuals taking semaglutide, the study identified a potential “dose-dependent safety concern.” Wegovy, marketed primarily for obesity treatment, delivers a higher dosage of semaglutide compared to Ozempic and Rybelsus, which may account for the observed increased risk.
The study meticulously analysed data from the US Food and Drug Administration’s adverse event reporting system, examining reports filed between December 2017 and December 2024. Researchers compared the incidence of Naion among users of various semaglutide formulations, including the weekly injectable versions of Ozempic and Wegovy, alongside daily Rybelsus tablets and tirzepatide injections.
Regulatory Responses and Expert Opinions
Following the emergence of these findings, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) issued a drug safety update in February, alerting healthcare providers to the potential risk of Naion associated with semaglutide. Dr Alison Cave, the MHRA’s chief safety officer, reassured patients that while the risk remains extremely low, it is crucial for both patients and healthcare professionals to be vigilant for symptoms.
However, some experts urge caution in interpreting these results. Dr Samantha Mann, a consultant ophthalmologist and lead for diabetic eye screening at the Royal College of Ophthalmologists, pointed out that the study’s reliance on reported side effects does not definitively establish causation. She noted that a rise in Naion cases has not been widely observed in her clinical practice at St Thomas’ Hospital in London, indicating the need for further research to validate these findings.
A spokesperson for Novo Nordisk, the manufacturer of semaglutide products, stressed the company’s commitment to patient safety and their ongoing collaboration with regulatory bodies to monitor the safety of their medications. They confirmed that updates have been made to patient information leaflets for Wegovy, Ozempic, and Rybelsus to include warnings about Naion but maintained that the overall benefit-risk profile of semaglutide remains favourable based on the current evidence.
Why it Matters
The implications of this study are profound, particularly as obesity rates continue to soar globally and demand for effective weight-loss treatments increases. The heightened risk of vision loss associated with Wegovy underscores the necessity for comprehensive risk assessments and informed patient discussions regarding potential side effects. As healthcare providers strive to balance the benefits of rapid weight loss with safety considerations, ongoing research and vigilance are essential to ensure that patients can make informed decisions about their treatment options. The findings serve as a crucial reminder of the complexities surrounding pharmaceutical interventions, where the promise of enhanced health must be weighed against potential risks.
